Healthy Extracts grows revenue but faces heavy dilution, going concern after Gummy USA deal

Quick take - Healthy Extracts Inc. (PINK: HYEX)
The company is generating growing revenue from nutraceuticals but remains debt‑ and derivative‑heavy with continued going concern disclosure. Management is investing in sales and marketing, issued large share consideration in July 2025 for an acquisition, and continues to rely on financing and conversions to fund operations.

Key points & stats
Revenue (3 months ended 6/30/2025): $968,656
Revenue (6 months ended 6/30/2025): $1,899,935 (up 19% YoY vs $1,597,175)
Gross profit (3 months): $592,827; Gross profit (6 months): $1,017,812
Net income/(loss): $67,120 (3 months); $(331,739) (6 months)
EPS (basic & diluted): $0.02 (Q2 2025); $(0.11) (6M 2025)
Cash (balance sheet at 6/30/2025): $200,495 (cash-flow table shows $200,494)
Total assets: $2,495,521; Total liabilities: $2,017,564; Stockholders' equity: $477,958
Derivative liabilities (fair value, 6/30/2025): $678,888 (Level 3)
Convertible debt, net: $247,423 (total convertible promissory notes outstanding balance) - notable is promissory note #4 balance $240,673
Inventory, net: $1,106,878; Inventory allowance: $233,115 (down from $781,759 at 12/31/2024)
General & administrative (3 months): $698,434 (advertising $254,511; consulting $106,700; stock-based comp $71,161)
Operating cash provided (six months): $77,237; Cash increase over period: ~$88k
Accumulated deficit: $(19,572,083) (through 6/30/2025)
Shares issued/outstanding: 3,141,490 shares issued/outstanding at 6/30/2025; subsequent events (July 2025) issued 13,075,920 shares for acquisition - total outstanding reported as of Aug 6, 2025: 16,870,868 shares

What's happening inside the company (straightforward)
- Sales growth: organic revenue gained - +7% Q2 YoY and +19% for 6M - management attributes this to direct consumer marketing and e‑commerce channels (BergaMet, UBN).
- Heavy financing activity: multiple notes, convertible debt, and derivative accounting. Convertible features are remeasured each period and drive large non‑cash swings in other income/(expense).
- Investing in demand generation: G&A and advertising spiked (advertising alone $254,511 in the quarter) to drive revenue growth.
- Balance sheet shifts: inventory was materially reduced and inventory allowance dropped sharply (from $781,759 to $233,115), freeing working capital but raising questions on previous valuation assumptions.
- Corporate action/subsequent events: large equity issuance in July 2025 (13,075,920 shares) to acquire Gummy USA LLC - this is highly dilutive and changes ownership (acquirer gets ~77.5% post‑deal). Management also issued shares for services (653,458 on July 18, plus other smaller issuances).

Income statement - positives
- Revenue growth: top line improved Q2 and for the six months (1,899,935 for 6M).
- Improved gross margin in Q2: cost of revenue % decreased (39% of revenue in Q2 vs 46% prior year quarter), showing production/fulfillment efficiencies.
- Q2 profitability: reported net income of $67,120 in the three‑month period (driven in part by favorable derivative fair value movement in the quarter).

Income statement - negatives / risks
- Operating expenses rising fast: G&A increased 40% YoY for the quarter to $698k; heavy advertising and consulting spend may pressure margins if sales growth slows.
- Earnings volatility from derivatives: change in fair value of derivative liabilities is a large non‑operating driver (Q2 showed a $201,986 positive change, but six‑month change was $(53,468)); this creates earnings swings unrelated to core operations.
- Continued net loss on six‑month basis: $(331,739) for 6M 2025 and an accumulated deficit of $(19.57M).
- High leverage vs equity: total liabilities $2.02M exceed equity $477,958; derivative liability alone ($678,888) exceeds equity and signals potential dilution or cash risk if conversions occur.
- Going concern flagged: auditors/management disclose substantial doubt and reliance on equity/debt financings - future financing likely dilutive.

Watch list (near term)
- Integration and revenue contribution from Gummy USA acquisition (July 19, 2025) and related dilution impact on per‑share metrics.
- Ability to convert operating revenue growth into sustained positive operating cash flow while containing G&A/ad spend.
- Convertible note and derivative exposures - potential future share issuance and remeasurement volatility.
- Inventory turnover and allowance assumptions (big allowance reduction vs prior period) - monitor for reversals or write‑downs.
- Debt service and covenant/timing on related‑party and secured/unsecured notes (several varied terms and repayment schedules).

Bottom line: Healthy Extracts is growing revenue and investing in marketing, which improved gross margins in Q2, but the business remains capital‑constrained and volatile from convertible/derivative accounting. The July 2025 equity issuance for the Gummy USA deal is transformational and highly dilutive - treat near‑term per‑share metrics and governance changes cautiously. Key next reports should clarify acquisition impact, integration results, and how management will stabilize capital structure.